Skip to main content

Advertisement

Table 1 PAK1 knock-down (KD) inhibits proliferation and increases gemcitabine sensitivity

From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

  Growth rate (%/h) Gemcitabine IC50 (nM)
PANC-1 MiaPaCa-2 PANC-1 MiaPaCa-2
NC1 2.4 2.9 26 ± 2 29 ± 1
NC2 2.6 2.7 39 ± 1 28 ± 1
KD1 1.9 * 2.0 ** 20 ± 2 ** 26 ± 1 *
KD2 2.1 * 2.1 ** 21 ± 2 * 25 ± 2 *
  1. NC1 and NC2 indicate PANC-1 NC clones NC1 and NC2; and MiaPaCa-2 NC clones NC2 and NC8 respectively. KD1 and KD2 indicate PANC-1 KD clones 2.05 and 2.10; and MiaPaCa-2 KD clones 3.09 and 3.12 respectively. * p < 0.05; ** p < 0.01, compared to either NC clone (only the higher p value of the two is presented)